From my understanding while HIV mutates, there are only 2 tropics referred to as R5 and X4 and some HIV cases are dual tropic that uses both receptors. ~70% of the HIV cases are R5, meaning they use the CCR5 receptor to spread. leronlimab works on only the R5 tropic because of the CCR5 affiliation.

My guess is that while corona virus may mutate and make a vaccine difficult or impossible, this will not impact leronlimab being successful or not. leronlimab's MOA in COVID-19 is not like HIV with the R5 tropic disease as COVID-19 uses the ACE 2 receptor which leronlimab has no direct impact, but as BP has mentioned leronlimab's MOA in COVID-19 is more like cancer or other auto-immune diseases where it helps regulate the immune response and restore a competent immune system (this also has a benefit of lowering the virus as the body is able to fight it better with a competent immune system). There is a point when COVID-19 transitions from a virus and becomes an auto-immune disease as BP explained on the Sunday Dr. Yo interview. Possibly 22 Cancers, GvHD, NASH, MS, moderate, severe and critical COVID-19, ARDS, severe influenza and various other diseases (see latest CytoDyn Presentation for a list of potential Immunology diseases or Ohms post) leronlimab has the potential to help by regulating the immune response to help the body not turn against itself and fight the disease the way it was built to do ......this is why leronlimab being successful in COVID-19 and proving MOA is HUGE!

We will know soon enough, but previous research on CCR5 in these indications, pre-clinical studies leronlimab has tested and early results in the cancer and COVID-19 studies are looking extremely promising to say the least......oh, by the way it helps when a drug that can accomplish this is extremely safe!